| Description | The XGv347 is a highly potent antibody against Omicron Spike S1 with IC50 values of 6 ng/ml. XGv347 bound Omicron S with 5- to 40-fold lower affinity compared with their binding to WT Spike. This product has been tested using Enzyme-linked immunosorbent assay, Bio-layer interferometry and Neutralization assay. |
| Clonality | Monoclonal |
| Host Species | Human |
| Target Species | SARS-CoV-2 (Omicron) |
| Immunogen | CoronaVac (Sinovac) inactivated virus vaccine |
| Epitope | The epitope at the tip of the RBD overlapping largely with the patch targeted by ACE2. |
| Expression Species | HEK293F or CHO cell line |
| Conjugation | Unconjugated |
| Purity | >95% |
| Endotoxin | <1 EU/mg |
| Form | Liquid |
| Purification | Protein A purified |
| Sterility | 0.2 μM filtered |
| Formulation | PBS, pH 7.4 |
| Preservation | No preservatives |
| Stabilizer | No stabilizers |
| Storage | Store at 4°C within one or two weeks. Store at -20°C for long term. Avoid repeated freeze/thaw cycles. Refer to the COA file for specifics. |
| Application | ELISA; BLI; Neut |
| Application Notes | This antibody has been tested by ELISA and Neutralization assay. The ELISA was done using antibody started at 25 μg/mL with a serial 1:2 dilution. The Neutralization assay of of XGv347 against Omicron was done with an IC50 value of 6 ng/mL. |
| ELISA | Enzyme-Linked Immunosorbent Assay Protocol |
| WB | Western Blot Protocol |
| FC | Flow Cytometry Protocol |
| Target | SARS-CoV-2 S1 |
| Alternative Name | Severe acute respiratory syndrome coronavirus 2 Spike S1 |
| Research Area | Coronavirus Disease 2019 |
| Related Disease | Coronavirus Disease 2019 |
